Looking into anti-angiogenic gene therapies for disorders of the eye.
Age-related macular degeneration (AMD) and proliferative diabetic retinopathy (DR) are the most common causes of visual impairment in the developed world. Because the key factor in AMD and DR is aberrant neovascularization in the retina (DR) or in the choroid (AMD), strategies to inhibit abnormal neovascularization represent a compelling therapeutic approach. Here we review various anti-angiogenic strategies for the treatment of ocular neovascular diseases with special emphasis on gene transfer as a way of achieving high, sustained concentrations of anti-angiogenic proteins in the back of the eye without concomitant systemic toxicity.
Rasmussen
Henrik S.
HS
GenVec, 65 West Watkins Mill Road, 20878, Gaithersburg, MD, USA
Rasmussen
Camilla S.
CS
Durham
Rebecca G.
RG
King
C Richter
CR
Wei
Lisa
L